BREAKING
Home » Posts Tagged "Achaogen"

Antibiotic challenges and the Melinta situation

By

By NewsDesk  @infectiousdiseasenews In late December 2019, antibiotic development and commercialization company, Melinta Therapeutics, Inc. initiated a voluntary Chapter 11 process to effectuate restructuring...

Investigational drug, Plazomicin, for treating multi-drug resistant (MDR) gram-negative infections gets FDA Priority Review

By

Achaogen, Inc.,  a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced this week that the U.S. Food and...

plague

‘Combating antibiotic-resistant infections is fundamental to U.S. biodefense’: BARDA director

By

The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services,...

Antibiotic candidate, Plazomicin, achieves positive results in Phase 3 clinical trials

By

Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that its lead product candidate,...